{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:34Z","timestamp":1792008094162,"version":"4.4.0"},"reference-count":271,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2531,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic activation of the renin-angiotensin-aldosterone system (RAAS) promotes and perpetuates the syndromes of congestive heart failure, systemic hypertension, and chronic kidney disease. Excessive circulating and tissue angiotensin II (AngII) and aldosterone levels lead to a pro-fibrotic, -inflammatory, and -hypertrophic milieu that causes remodeling and dysfunction in cardiovascular and renal tissues. Understanding of the role of the RAAS in this abnormal pathologic remodeling has grown over the past few decades and numerous medical therapies aimed at suppressing the RAAS have been developed. Despite this, morbidity from these diseases remains high. Continued investigation into the complexities of the RAAS should help clinicians modulate (suppress or enhance) components of this system and improve quality of life and survival. This review focuses on updates in our understanding of the RAAS and the pathophysiology of AngII and aldosterone excess, reviewing what is known about its suppression in cardiovascular and renal diseases, especially in the cat and dog.<\/jats:p>","DOI":"10.1111\/jvim.15454","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T08:37:41Z","timestamp":1551170261000},"page":"363-382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":389,"title":["The renin-angiotensin-aldosterone system and its suppression"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-6123","authenticated-orcid":false,"given":"Marisa K.","family":"Ames","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, Colorado State University Department of Clinical Sciences, , Fort Collins, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarke E.","family":"Atkins","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, North Carolina State University Department of Clinical Sciences, , Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan School of Medicine Department of Medicine, , Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"issue":"2","key":"2026020922225289500_jvim15454-bib-0001","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0002","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/01.CIR.96.2.526","article-title":"Hormonal changes and catabolic\/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia","volume":"96","author":"Anker","year":"1997","journal-title":"Circulation"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0003","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/oxfordjournals.eurheartj.a059429","article-title":"Neuroendocrine response in acute heart failure and the influence of treatment","volume":"10","author":"Broqvist","year":"1989","journal-title":"Eur Heart J"},{"key":"2026020922225289500_jvim15454-bib-0004","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/0002-9149(82)90243-0","article-title":"Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure","volume":"49","author":"Levine","year":"1982","journal-title":"Am J Cardiol"},{"key":"2026020922225289500_jvim15454-bib-0005","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0006","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0007","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium. Fibrosis and renin- angiotensin-aldosterone system","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation"},{"key":"2026020922225289500_jvim15454-bib-0008","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/01.HYP.19.3.270","article-title":"Aldosterone reduces baroreceptor discharge in the dog","volume":"19","author":"Wang","year":"1992","journal-title":"Hypertens"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0009","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/eurheartj\/16.suppl_O.107","article-title":"The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure","volume":"16","author":"Brilla","year":"1995","journal-title":"Eur Heart J"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10557-010-6256-6","article-title":"Aldosterone inhibition and cardiovascular protection: more important than it once appeared","volume":"24","author":"Martinez","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0011","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","article-title":"Effects of aldosterone on the vasculature","volume":"47","author":"Schiffrin","year":"2006","journal-title":"Hypertension"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0012","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2174\/157016111796642689","article-title":"Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage","volume":"9","author":"Waanders","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0013","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MED.0b013e3283391989","article-title":"Aldosterone and inflammation","volume":"17","author":"Gilbert","year":"2010","journal-title":"Curr Op Endocrinol Diabetes Obes"},{"key":"2026020922225289500_jvim15454-bib-0014","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1172\/JCI117269","article-title":"Mineralocorticoids, hypertension, and cardiac fibrosis","volume":"93","author":"Young","year":"1994","journal-title":"J Clin Invest"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0016","first-page":"1228","article-title":"Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial","volume":"15","author":"Girerd","year":"2014","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0017","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2125.1981.tb01231.x","article-title":"Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension","volume":"12","author":"Lijnen","year":"1981","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0018","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0019","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/hr.2013.74","article-title":"Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist","volume":"36","author":"Sato","year":"2013","journal-title":"Hypertens Res"},{"key":"2026020922225289500_jvim15454-bib-0020","first-page":"13","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy","volume":"29","author":"Sato","year":"2001","journal-title":"J Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0021","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0022","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"2026020922225289500_jvim15454-bib-0023","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0735-1097(01)01714-4","article-title":"Neurohormonal and clinicalresponses to high- versus low-dose enalapril therapy in chronic heart failure","volume":"39","author":"Tang","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026020922225289500_jvim15454-bib-0024","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/S0735-1097(01)01237-2","article-title":"Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype","volume":"37","author":"Cicoira","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0025","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jash.2012.07.003","article-title":"Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy","volume":"6","author":"Bomback","year":"2012","journal-title":"J Am Soc Hypertens"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0026","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.amjhyper.2007.09.001","article-title":"Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus","volume":"20","author":"Yoneda","year":"2007","journal-title":"Am J Hypertens"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0027","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","article-title":"How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?","volume":"82","author":"MacFadyen","year":"1999","journal-title":"Heart"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0028","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1388-9842(99)00046-X","article-title":"Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study","volume":"1","author":"Lee","year":"1999","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0029","first-page":"462","article-title":"Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy","volume":"11","author":"Horita","year":"2006","journal-title":"Nephrol Ther"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u201cEscape\u201d of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0031","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2005.02.016","article-title":"Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition","volume":"106","author":"van de Wal","year":"2006","journal-title":"Int J Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0032","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/euhj.1999.1740","article-title":"Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure","volume":"21","author":"Roig","year":"2000","journal-title":"Eur Heart J"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0033","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0002-9149(02)03119-3","article-title":"Neurohormonal prediction of mortality following admission for decompensated heart failure","volume":"91","author":"Aronson","year":"2003","journal-title":"Am J Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0034","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics","volume":"57","author":"Bayliss","year":"1987","journal-title":"Br Heart J"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0035","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2460\/javma.1983.183.09.991","article-title":"Comparison of plasma aldosterone concentration among clinical status groups","volume":"183","author":"Knowlen","year":"1983","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0036","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2460\/ajvr.2001.62.1793","article-title":"Additive effects of a sodium chloride restricted diet and furosemide administration in healthy dogs","volume":"62","author":"Lovern","year":"2001","journal-title":"Am J Vet Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0037","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2460\/ajvr.1996.57.11.1645","article-title":"Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation","volume":"57","author":"Haggstrom","year":"1996","journal-title":"Am J Vet Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0038","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-2885.2007.00894.x","article-title":"The effect of amlodipine and the combination of amlodipine and enalapril on the renin-angiotensin-aldosterone system in the dog","volume":"30","author":"Atkins","year":"2007","journal-title":"J Vet Pharmacol Ther."},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0039","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.2460\/ajvr.72.12.1646","article-title":"Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs","volume":"72","author":"Lantis","year":"2011","journal-title":"Am J Vet Res"},{"key":"2026020922225289500_jvim15454-bib-0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fendo.2014.00016","article-title":"Clinical perspectives and fundamental aspects of local cardiovascular and renal Renin-Angiotensin systems","volume":"5","author":"De Mello","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026020922225289500_jvim15454-bib-0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2015.00072","article-title":"Chemical communication between heart cells is disrupted by intracellular renin and angiotensin ii: implications for heart development and disease","volume":"6","author":"De Mello","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0042","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00424-012-1120-0","article-title":"ACE2, angiotensin-(1\u20137), and Mas: the other side of the coin","volume":"465","author":"Bader","year":"2013","journal-title":"Pflugers Arch"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0043","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1440-1681.2005.04201.x","article-title":"The \u201cbody fluid pressure control system\u201d relies on the renin-angiotensin-aldosterone system: balance studies in freely moving dogs","volume":"32","author":"Seelinger","year":"2005","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2026020922225289500_jvim15454-bib-0044","first-page":"213","article-title":"Guyton and Hall Textbook of Medical Physiology","author":"Hall","year":"2010"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0045","first-page":"R85","article-title":"Regulation of aldosterone secretion: from physiology to disease","volume":"168","author":"Beuschlein","year":"2013","journal-title":"J Endocrinol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0046","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1126\/science.2845584","article-title":"Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated","volume":"242","author":"Funder","year":"1988","journal-title":"Science"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0047","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1210\/endo-125-4-2224","article-title":"Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors","volume":"125","author":"Funder","year":"1989","journal-title":"Endocrinology"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0048","first-page":"49","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2015","journal-title":"Pharmacol Rev"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0049","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.mce.2011.09.011","article-title":"The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism","volume":"350","author":"Marzolla","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2026020922225289500_jvim15454-bib-0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.steroids.2014.05.001","article-title":"Mineralocorticoid receptor in adipocytes and macrophages: a promising target to fight metabolic syndrome","volume":"91","author":"Marzolla","year":"2014","journal-title":"Steroids"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0051","first-page":"965","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0052","doi-asserted-by":"crossref","first-page":"C532","DOI":"10.1152\/ajpcell.00203.2012","article-title":"Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation","volume":"304","author":"Gros","year":"2013","journal-title":"Am J Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0053","doi-asserted-by":"crossref","first-page":"T23","DOI":"10.1530\/JOE-17-0060","article-title":"30 years of the mineralocorticoid receptor: coregulators as mediators of mineralocorticoid receptor signalling diversity","volume":"234","author":"Fuller","year":"2017","journal-title":"J Endocrinol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0054","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev.pharmtox.010909.105610","article-title":"Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy","volume":"50","author":"Bader","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0055","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00109-008-0336-0","article-title":"Update on tissue renin\u2013angiotensin systems","volume":"86","author":"Bader","year":"2008","journal-title":"J Mol Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0056","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/01.HYP.25.2.170","article-title":"Production of aldosterone in isolated rat blood vessels","volume":"25","author":"Takeda","year":"1995","journal-title":"Hypertension"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0057","doi-asserted-by":"crossref","first-page":"1L","DOI":"10.1016\/S0002-9149(01)01878-1","article-title":"The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data","volume":"88","author":"Dzau","year":"2001","journal-title":"Am J Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0058","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/FJC.0b013e3181a717f7","article-title":"Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide","volume":"53","author":"Harada","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0059","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/01.HYP.20.1.67","article-title":"Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses","volume":"20","author":"Ullian","year":"1992","journal-title":"Hypertension"},{"key":"2026020922225289500_jvim15454-bib-0060","doi-asserted-by":"crossref","first-page":"C1525","DOI":"10.1152\/ajpcell.1993.264.6.C1525","article-title":"Angiotensin II-aldosterone interactions on protein synthesis in vascular smooth muscle cells","volume":"264","author":"Ullian","year":"1993","journal-title":"Am J Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0061","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jcp.1041610203","article-title":"Mechanisms of enhanced angiotensin","volume":"161","author":"Ullian","year":"1994","journal-title":"J Cell Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0062","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.CIR.104.2.137","article-title":"Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes","volume":"104","author":"Harada","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0063","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/HYPERTENSIONAHA.108.114223","article-title":"Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes","volume":"52","author":"Rossier","year":"2008","journal-title":"Hypertension"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0064","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.107.090472","article-title":"Angiotensin II-dependent superoxide: effects on hypertension and vascular dysfunction","volume":"52","author":"Welch","year":"2008","journal-title":"Hypertension"},{"key":"2026020922225289500_jvim15454-bib-0065","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1074\/jbc.273.9.4883","article-title":"Myocardial production of aldosterone and corticosterone in the rat physiological regulation","volume":"273","author":"Silvestre","year":"1998","journal-title":"J Biol Chem"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0066","doi-asserted-by":"crossref","first-page":"H139","DOI":"10.1152\/ajpheart.00373.2017","article-title":"The prorenin receptor in the cardiovascular system and beyond","volume":"314","author":"Hennrikus","year":"2018","journal-title":"Am J Phyisol Heart Circ Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0067","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","article-title":"Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin","volume":"109","author":"Nguyen","year":"2002","journal-title":"J Clin Invest"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0068","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bbrc.2013.10.124","article-title":"Big angiotensin-25: a novel glycosylated angiotensin-related peptide isolated from human urine","volume":"441","author":"Nagata","year":"2013","journal-title":"Biochem Biophys Res Comm"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0069","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bbrc.2006.09.146","article-title":"Isolation and identification of proangiotensin-12, a possible component of the renin\u2013angiotensin system","volume":"350","author":"Nagata","year":"2006","journal-title":"Biochem Biophys Res Comm"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0070","doi-asserted-by":"crossref","first-page":"22348","DOI":"10.1016\/S0021-9258(18)45712-2","article-title":"Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart","volume":"265","author":"Urata","year":"1990","journal-title":"J Biol Chem"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0071","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/01.RES.66.4.883","article-title":"Angiotensin II-forming pathways in normal and failing human hearts","volume":"66","author":"Urata","year":"1990","journal-title":"Circ Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0072","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1172\/JCI116325","article-title":"Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart","volume":"91","author":"Urata","year":"1993","journal-title":"J Clin Invest"},{"key":"2026020922225289500_jvim15454-bib-0073","first-page":"H404","article-title":"Intracrine angiotensin II functions originate from noncanonical pathways in the human heart","author":"Ferrario","year":"2016"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0074","doi-asserted-by":"crossref","first-page":"e28501","DOI":"10.1371\/journal.pone.0028501","article-title":"Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue","volume":"6","author":"Ahmad","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0075","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/CIRCRESAHA.117.310978","article-title":"Multifunctional role of chymase in acute and chronic tissue injury and remodeling","volume":"122","author":"Dell'Italia","year":"2018","journal-title":"Circ Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0076","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1124\/jpet.103.061465","article-title":"An antiarrhythmic effect of a chymase inhibitor after myocardial infarction","volume":"309","author":"Jin","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0077","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/01.CIR.0000074041.81728.79","article-title":"Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure","volume":"107","author":"Matsumoto","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0078","doi-asserted-by":"crossref","first-page":"e94732","DOI":"10.1371\/journal.pone.0094732","article-title":"Chymase mediates injury and mitochondrial damage in cardiomyocytes during acute ischemia\/reperfusion in the dog","volume":"9","author":"Zheng","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0079","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrcardio.2015.117","article-title":"Mast cells in human and experimental cardiometabolic diseases","volume":"12","author":"Shi","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0080","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0022-2828(03)00013-0","article-title":"Cardiac mast cell- and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog","volume":"35","author":"Stewart","year":"2003","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0081","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jvc.2012.01.012","article-title":"Left ventricular remodeling in preclinical experimental mitral regurgitation of dogs","volume":"14","author":"Dillon","year":"2012","journal-title":"J Vet Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0082","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0735-1097(02)01763-1","article-title":"Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog","volume":"39","author":"Perry","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0083","first-page":"H961","article-title":"Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs","volume":"273","author":"Dell'Italia","year":"1997","journal-title":"Am J Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0084","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2460\/ajvr.69.12.1574","article-title":"Comparison of the effects of candesartan cilexetil and enalapril maleate on right ventricular myocardial remodeling in dogs with experimentally induced pulmonary stenosis","volume":"69","author":"Yamane","year":"2008","journal-title":"Am J Vet Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0085","doi-asserted-by":"crossref","first-page":"H137","DOI":"10.1152\/ajpheart.00618.2015","article-title":"Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?","volume":"310","author":"Chappell","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0086","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/HYPERTENSIONAHA.106.076216","article-title":"Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure?","volume":"50","author":"Chappell","year":"2007","journal-title":"Hypertension"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0087","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-5793(94)01292-9","article-title":"Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues","volume":"357","author":"Metzger","year":"1995","journal-title":"FEBS Lett"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0088","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1113\/jphysiol.2010.203075","article-title":"Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor","volume":"589","author":"Flores-Mu\u00f1oz","year":"2011","journal-title":"J Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0089","doi-asserted-by":"crossref","first-page":"e00151","DOI":"10.1002\/phy2.151","article-title":"Cardioprotective effects of angiotensin III against ischemic injury via the AT2 receptor and KATP channels","volume":"1","author":"Park","year":"2013","journal-title":"Physiol Rep"},{"key":"2026020922225289500_jvim15454-bib-0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.peptides.2013.01.018","article-title":"Angiotensin III stimulates high stretch-induced ANP secretion via angiotensin type 2 receptor","volume":"42","author":"Park","year":"2013","journal-title":"Peptides"},{"key":"2026020922225289500_jvim15454-bib-0091","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.peptides.2014.10.016","article-title":"Angiotensin IV stimulates high atrial stretch-induced ANP secretion via insulin regulated aminopeptidase","volume":"63","author":"Park","year":"2015","journal-title":"Peptides"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0092","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0031-9384(85)90332-4","article-title":"Day-night variations in urine excretions and hormones in dogs: role of autonomic innervation","volume":"35","author":"Gordon","year":"1985","journal-title":"Physiol Behav"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0093","first-page":"636","article-title":"Circadian variations of total renin and active renin","volume":"22","author":"Kawasaki","year":"2008","journal-title":"Horm Metab Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0094","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0378-5122(81)90009-8","article-title":"Ageing and circadian rhythm of plasma renin and aldosterone","volume":"3","author":"Cugini","year":"1981","journal-title":"Maturitas"},{"key":"2026020922225289500_jvim15454-bib-0095","first-page":"1","article-title":"A Time for Metabolism and Hormones","author":"Sassone-Corsi","year":"2016"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0096","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0165-1838(95)00070-4","article-title":"Changes of blood pressure, sodium excretion and sodium balance due to variations of the renin-angiotensin-aldosterone system","volume":"57","author":"Reinhardt","year":"1996","journal-title":"J Auton Nerv Syst"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0097","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3109\/07420528.2013.807275","article-title":"Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology","volume":"30","author":"Mochel","year":"2013","journal-title":"Chronobiol Int"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0098","first-page":"431","article-title":"Chronobiological analysis techniques. Application to blood pressure","volume":"367","author":"Fernandez","year":"2009","journal-title":"Philos Trans A Math Phys Eng Sci"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0099","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3109\/07420528.2014.897711","article-title":"Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs","volume":"31","author":"Mochel","year":"2014","journal-title":"Chronobiol Int"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0100","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.jacc.2010.11.022","article-title":"The primary benefits of angiotensin-converting enzyme inhibition on cardiac remodeling occur during sleep time in murine pressure overload hypertrophy","volume":"57","author":"Martino","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0101","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00125-015-3749-7","article-title":"Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial","volume":"59","author":"Hermida","year":"2015","journal-title":"Diabetologia"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0102","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1113\/jphysiol.2014.271676","article-title":"Pressure natriuresis and the renal control of arterial blood pressure","volume":"592","author":"Ivy","year":"2014","journal-title":"J Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0103","first-page":"R865","article-title":"Long-term arterial pressure control: an analysis from animal experiments and computer and graphic models","volume":"259","author":"Guyton","year":"1990","journal-title":"Am J Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0104","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/BF02584211","article-title":"Systems analysis of arterial pressure regulation and hypertension","volume":"1","author":"Guyton","year":"1972","journal-title":"Ann Biomed Eng"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0105","first-page":"F627","article-title":"Mechanisms of escape from sodium retention during angiotensin II hypertension","volume":"246","author":"Hall","year":"1984","journal-title":"Am J Physiol"},{"key":"2026020922225289500_jvim15454-bib-0106","first-page":"43","article-title":"Reviews of Physiology, Biochemistry and Pharmacology","author":"Mochel","year":"2015"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0107","first-page":"R1","article-title":"Determinants of the natriuresis after acute, slow sodium loading in conscious dogs","volume":"278","author":"Bie","year":"2000","journal-title":"Am J Physiol Reg Comp Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0108","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1161\/01.HYP.0000175814.18550.c0","article-title":"Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor","volume":"46","author":"Xue","year":"2005","journal-title":"Hypertension"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0109","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/j.jacc.2016.10.017","article-title":"Renin-angiotensin system fingerprints of heart failure with reduced ejection fraction","volume":"68","author":"Pavo","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0110","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","article-title":"Roles of angiotensin peptides and recombinant human ACE2 in heart failure","volume":"69","author":"Basu","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026020922225289500_jvim15454-bib-0111","first-page":"174","article-title":"Capturing the dynamics of systemic renin-angiotensin-aldosterone system (RAAS) peptides heightens the understanding of the effect of benazepril in dogs","author":"Mochel","year":"2012"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0112","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jvc.2017.03.001","article-title":"Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease","volume":"19","author":"Ames","year":"2017","journal-title":"J Vet Cardiol"},{"key":"2026020922225289500_jvim15454-bib-0113","first-page":"1","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0114","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.pharmthera.2013.11.006","article-title":"The cardioprotective effects of mineralocorticoid receptor antagonists","volume":"142","author":"van den Berg","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0115","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1161\/01.CIR.88.6.2849","article-title":"Identification of functional angiotensin II receptors on rat cardiac fibroblasts","volume":"88","author":"Villarreal","year":"1993","journal-title":"Circulation"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0116","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1161\/hh0901.090299","article-title":"Novel gp91(phox) homologues in vascular smooth muscle cells : nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways","volume":"88","author":"Lass\u00e8gue","year":"2001","journal-title":"Circ Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0117","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1161\/CIRCRESAHA.107.152439","article-title":"Ets-1 is a critical transcriptional regulator of reactive oxygen species and p47phox gene expression in response to angiotensin II","volume":"101","author":"Ni","year":"2007","journal-title":"Circ Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0118","doi-asserted-by":"crossref","first-page":"8D","DOI":"10.1016\/S0002-9149(99)80485-8","article-title":"Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover","volume":"76","author":"Brilla","year":"1995","journal-title":"Am J Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0119","first-page":"H1861","article-title":"Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen","volume":"262","author":"Villarreal","year":"1992","journal-title":"Am J Physiol"},{"key":"2026020922225289500_jvim15454-bib-0120","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1161\/HYPERTENSIONAHA.111.190512","article-title":"Aldosterone inhibits antifibrotic factors in mouse hypertensive heart","volume":"59","author":"Azibani","year":"2012","journal-title":"Hypertension"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0121","first-page":"623","article-title":"aldosterone\/NaCl-induced renal and cardiac","volume":"34","author":"Schreier","year":"2011","journal-title":"Hypertension"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0122","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/01.CIR.0000121426.43044.2B","article-title":"Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy","volume":"109","author":"Tsybouleva","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0123","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/01.HYP.21.3.294","article-title":"Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats","volume":"21","author":"Lariviere","year":"1993","journal-title":"Hypertension"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0124","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/bjp.2008.200","article-title":"Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin","volume":"154","author":"Xavier","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0125","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/01.HYP.0000171184.84077.80","article-title":"Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts","volume":"46","author":"Fujita","year":"2005","journal-title":"Hypertension"},{"key":"2026020922225289500_jvim15454-bib-0126","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0895-7061(04)00811-8","article-title":"Involvement of oxidative stress in the profibrotic action of aldosterone: interaction with the renin-angiotensin system","volume":"17","author":"Iglarz","year":"2004","journal-title":"Am J Hypertens"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0127","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0922-4106(95)90018-7","article-title":"Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta","volume":"290","author":"Ikeda","year":"1995","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0128","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1161\/01.RES.0000163017.13772.3a","article-title":"CCL2\/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts","volume":"96","author":"Dewald","year":"2005","journal-title":"Circ Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0129","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1046\/j.1523-1755.2003.00767.x","article-title":"Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice","volume":"63","author":"Persy","year":"2003","journal-title":"Kidney Int"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","article-title":"Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure","volume":"54","author":"Rickard","year":"2009","journal-title":"Hypertension"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0131","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1210\/en.2011-2098","article-title":"Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis","volume":"153","author":"Bienvenu","year":"2012","journal-title":"Endocrinology"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0132","doi-asserted-by":"crossref","first-page":"R879","DOI":"10.1152\/ajpregu.00075.2014","article-title":"Cardiac macrophages and apoptosis after myocardial infarction: effects of central MR blockade","volume":"307","author":"Rafatian","year":"2014","journal-title":"Am J Physiol Reg Comp Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0133","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J Clin Invest"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0134","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.107.091058","article-title":"Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress","volume":"50","author":"Nagase","year":"2007","journal-title":"Hypertension"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0135","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/HJH.0b013e328300a232","article-title":"Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions","volume":"26","author":"Wang","year":"2008","journal-title":"J Hypertens"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0136","first-page":"H190","article-title":"Aldosterone impairs baroreflex sensitivity in healthy adults","volume":"292","author":"Monahan","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0137","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/01.HYP.24.5.571","article-title":"Chronic administration of aldosterone depresses baroreceptor reflex function in the dog","volume":"24","author":"Wang","year":"1994","journal-title":"Hypertension"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0138","first-page":"2","article-title":"Novel mechanisms of sympatho-excitation in chronic heart failure","volume":"3","author":"Zucker","year":"2002","journal-title":"Heart Fail Monit"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0139","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM197110142851602","article-title":"Defective cardiac parasympathetic control in patients with heart disease","volume":"285","author":"Eckberg","year":"1971","journal-title":"N Engl J Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0140","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1161\/01.CIR.96.10.3450","article-title":"Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications","volume":"96","author":"Mortara","year":"1997","journal-title":"Circulation"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0141","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/hrt.73.6.517","article-title":"Baroreflex sensitivity and cardiovascular mortality in patients with mild to moderate heart failure","volume":"73","author":"Osterziel","year":"1995","journal-title":"Br Heart J"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0142","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2174\/138161207780618830","article-title":"Angiotensin-converting enzyme inhibitors in veterinary medicine","volume":"13","author":"Lefebvre","year":"2007","journal-title":"Curr Pharm Des"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0143","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0022-3565(24)35393-5","article-title":"Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic\/pharmacodynamic modeling approach","volume":"292","author":"Toutain","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0144","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2165\/00003088-199325040-00003","article-title":"Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview","volume":"25","author":"MacFadyen","year":"1993","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0145","doi-asserted-by":"crossref","first-page":"11945","DOI":"10.1016\/S0021-9258(18)80158-2","article-title":"Mouse angiotensin-converting enzyme is a protein composed of two homologous domains","volume":"264","author":"Bernstein","year":"1989","journal-title":"J Biol Chem"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0146","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1074\/jbc.270.8.3656","article-title":"The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme","volume":"270","author":"Rousseau","year":"1995","journal-title":"J Biol Chem"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0147","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.amjhyper.2004.09.004","article-title":"Inhibition of brain angiotensin-converting enzyme by peripheral administration of trandolapril versus lisinopril in Wistar rats","volume":"18","author":"Tan","year":"2005","journal-title":"Am J Hypertens"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0148","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1172\/JCI119529","article-title":"Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces","volume":"100","author":"Dell'Italia","year":"1997","journal-title":"J Clin Invest"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0149","doi-asserted-by":"crossref","first-page":"H2254","DOI":"10.1152\/ajpheart.00191.2001","article-title":"Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene","volume":"282","author":"Wei","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0150","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2460\/ajvr.69.3.343","article-title":"Evaluation of the renin-angiotensin system in cardiac tissues of cats with pressure-overload cardiac hypertrophy","volume":"69","author":"Uechi","year":"2008","journal-title":"Am J Vet Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0151","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2008.01.003","article-title":"Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure","volume":"19","author":"Carey","year":"2008","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0152","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0153","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0154","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","article-title":"Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors","volume":"40","author":"Maggioni","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0155","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0156","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.amjcard.2009.11.044","article-title":"Current status of dual renin angiotensin aldosterone system blockade for the treatment of cardiovascular diseases","volume":"105","author":"Chrysant","year":"2010","journal-title":"Am J Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0157","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jvc.2007.10.002","article-title":"Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs","volume":"9","author":"Jeunesse","year":"2007","journal-title":"J Vet Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0158","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0090-9556(25)06095-7","article-title":"Species differences in the metabolism and disposition of spironolactone","volume":"4","author":"Karim","year":"1976","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0159","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/jps.2600610720","article-title":"Plasma levels of spirolactones in the dog","volume":"61","author":"Sadee","year":"1972","journal-title":"J Pharm Sci"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0160","first-page":"260","article-title":"A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog","volume":"33","author":"Guyonnet","year":"2010","journal-title":"J Vet Pharmacol Ther"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0161","first-page":"469","article-title":"Gynecomastia and antihypertensive therapy","volume":"6","author":"Mosenkis","year":"2004","journal-title":"J Clin Hypertens"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0162","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1677\/joe.0.0840371","article-title":"Interaction of spironolactone with oestradiol receptors in cytosol","volume":"84","author":"Levy","year":"1980","journal-title":"J Endocrinol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0163","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/0003-4819-87-4-398","article-title":"Pathophysiology of spironolactone-induced gynecomastia","volume":"87","author":"Rose","year":"1977","journal-title":"Ann Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0164","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0165","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0166","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Aliskiren, enalapril, or aliskiren and enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0167","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"2026020922225289500_jvim15454-bib-0168","first-page":"1","article-title":"Aldosterone synthase inhibitors in hypertension: current status and future possibilities","volume":"3","author":"Hargovan","year":"2014","journal-title":"JRSM Cardiovasc Dis"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0169","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(16)30969-2","article-title":"Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure","volume":"389","author":"Packer","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0170","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013Neprilysin Inhibition versus Enalapril in Heart Failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0171","first-page":"1476","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"68","author":"Writing Committee Members","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026020922225289500_jvim15454-bib-0172","doi-asserted-by":"crossref","first-page":"A806","DOI":"10.1016\/S0735-1097(14)60806-8","article-title":"First-in-class angiotensin receptor neprilysin inhibitor LCZ696 modulates the dynamics of the renin cascade and natriuretic peptides system with significant reduction","volume":"63","author":"Mochel","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0173","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/j.1939-1676.2009.0392.x","article-title":"Guidelines for the diagnosis and treatment of canine chronic valvular heart disease","volume":"23","author":"Atkins","year":"2009","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0174","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/jvim.15240","article-title":"A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril\/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease","volume":"32","author":"Newhard","year":"2018","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0175","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/angiotensin 1\u20137 axis of the Renin\u2013Angiotensin system in heart failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circ Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0176","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.110.955369","article-title":"Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction","volume":"122","author":"Zhong","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0177","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0178","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/CIRCHEARTFAILURE.113.000672","article-title":"Angiotensin 1\u20137 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db\/db mice by reducing lipotoxicity and inflammation","volume":"7","author":"Mori","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0179","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0181","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0140-6736(92)92889-N","article-title":"Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions","volume":"340","author":"Yusuf","year":"1992","journal-title":"Lancet"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0182","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1760-2734(06)70053-4","article-title":"Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure","volume":"6","author":"Amberger","year":"2004","journal-title":"J Vet Cardiol"},{"key":"2026020922225289500_jvim15454-bib-0183","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2460\/javma.1998.213.11.1573","article-title":"Effects of enalapril maleate on survival of dogs with naturally occurring acquired heart failure","volume":"213","author":"Ettinger","year":"1998","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922225289500_jvim15454-bib-0184","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1760-2734(06)70025-X","article-title":"The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial","volume":"1","author":"BENCH (BENazepril in Canine Heart Disease) Study Group","year":"1999","journal-title":"J Vet Cardiol"},{"key":"2026020922225289500_jvim15454-bib-0185","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1939-1676.1995.tb01075.x","article-title":"Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group","volume":"9","author":"The COVE Study Group","year":"1995","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0186","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1748-5827.2006.00170.x","article-title":"Clinical evaluation of imidapril in congestive heart failure in dogs: results of the EFFIC study","volume":"48","author":"Besche","year":"2007","journal-title":"J Small Anim Pract"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0187","first-page":"234","article-title":"Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril Study","volume":"9","author":"The IMPROVE Study Group","year":"1995","journal-title":"J Vet Intern Med"},{"key":"2026020922225289500_jvim15454-bib-0188","author":"FDA New Drug Application"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0189","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1939-1676.2008.0150.x","article-title":"Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST Study","volume":"22","author":"H\u00e4ggstr\u00f6m","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0190","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1939-1676.2002.tb01610.x","article-title":"Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation","volume":"16","author":"Kvart","year":"2002","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0191","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2460\/javma.231.7.1061","article-title":"Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency","volume":"231","author":"Atkins","year":"2007","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0192","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1939-1676.2008.0105.x","article-title":"Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases","volume":"22","author":"Pouchelon","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0193","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1939-1676.2009.0346.x","article-title":"Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in doberman pinschers","volume":"23","author":"O'Grady","year":"2009","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0194","first-page":"1","article-title":"Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism","volume":"18","author":"Meurs","year":"2017","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1532-950X.1990.tb01178.x","article-title":"Captopril provides sustained hemodynamic benefits in dogs with experimentally induced mitral regurgitation","volume":"19","author":"Blackford","year":"1990","journal-title":"Vet Surg"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0196","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/jvim.14586","article-title":"Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: The EPIC Study-a randomized clinical trial","volume":"30","author":"Boswood","year":"2016","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0197","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026020922225289500_jvim15454-bib-0198","first-page":"1309","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","author":"Pitt","year":"2003"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0199","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0200","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cardfail.2012.02.005","article-title":"Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee","volume":"18","author":"Butler","year":"2012","journal-title":"J Card Fail"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0201","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(02)02382-3","article-title":"Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy","volume":"40","author":"Rousseau","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0202","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1439-0442.1995.tb00397.x","article-title":"Breed differences in the plasma renin activity and plasma aldosterone concentration of dogs","volume":"42","author":"Pedersen","year":"1995","journal-title":"Zentralbl Veterinarmed A"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0203","first-page":"65","article-title":"Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs","volume":"38","author":"Lantis","year":"2014","journal-title":"J Vet Pharmacol Ther"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0204","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jvp.12216","article-title":"The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs","volume":"38","author":"Lantis","year":"2015","journal-title":"J Vet Pharmacol Ther"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0205","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2460\/ajvr.76.12.1041","article-title":"Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs","volume":"76","author":"Ames","year":"2015","journal-title":"Am J Vet Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0206","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","article-title":"Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure","volume":"106","author":"Suzuki","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0207","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1161\/hc0502.102962","article-title":"Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure","volume":"105","author":"Cataliotti","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0208","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/jvim.13587","article-title":"Pathologic manifestations on surgical biopsy and their correlation with clinical indices in dogs with degenerative mitral valve disease","volume":"29","author":"Lee","year":"2015","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0209","first-page":"322","article-title":"Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs","volume":"34","author":"Schuller","year":"2010","journal-title":"J Vet Pharmacol Ther"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1939-1676.2009.0467.x","article-title":"Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease","volume":"24","author":"Bernay","year":"2010","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0211","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0212","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0213","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0214","first-page":"1","article-title":"Spironolactone metabolites in TOPCAT - new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0215","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jacbts.2016.03.001","article-title":"Detection and management of geographic disparities in the TOPCAT trial","volume":"1","author":"Bristow","year":"2016","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0216","doi-asserted-by":"crossref","first-page":"e001937","DOI":"10.1161\/CIRCHEARTFAILURE.114.001937","article-title":"Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial","volume":"9","author":"Lewis","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0217","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2016.07.763","article-title":"Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction","volume":"68","author":"Kosmala","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0218","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/j.1939-1676.2006.tb00707.x","article-title":"The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in maine coon cats with familial hypertrophic cardiomyopathy without heart failure","volume":"20","author":"MacDonald","year":"2006","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0219","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1939-1676.2008.0049.x","article-title":"Effect of spironolactone on diastolic function and left ventricular mass in maine coon cats with familial hypertrophic cardiomyopathy","volume":"22","author":"MacDonald","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jvc.2017.11.001","article-title":"The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy","volume":"20","author":"James","year":"2018","journal-title":"J Vet Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0221","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0222","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1470320314532509","article-title":"A pilot study of the effects of eplerenone add-on therapy in patients taking renin-angiotensin system blockers","volume":"16","author":"Kawada","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0223","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","article-title":"Aldosterone-receptor antagonism in hypertension","volume":"27","author":"Jansen","year":"2009","journal-title":"J Hypertens"},{"key":"2026020922225289500_jvim15454-bib-0224","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1939-1676.2007.tb03005.x","article-title":"Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats","volume":"21","author":"Brown","year":"2007","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0225","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2460\/javma.1996.209.10.1724","article-title":"Systemic arterial blood pressure and urine protein\/creatinine ratio in dogs with hyperadrenocorticism","volume":"209","author":"Ortega","year":"1996","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0226","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/vr.153.17.521","article-title":"Plasma aldosterone concentrations and plasma renin activity in healthy dogs and dogs with hyperadrenocorticism","volume":"153","author":"Javadi","year":"2003","journal-title":"Vet Rec"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0227","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1748-5827.2002.tb00019.x","article-title":"Investigation of the role of aldosterone in hypertension associated with spontaneous pituitary-dependent hyperadrenocorticism in dogs","volume":"43","author":"Goy-Thollot","year":"2002","journal-title":"J Small Anim Pract"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0228","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2460\/ajvr.2004.65.1245","article-title":"Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism","volume":"65","author":"Wenger","year":"2004","journal-title":"Am J Vet Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0229","first-page":"144","article-title":"Plasma renin activity and aldosterone concentrations in hypertensive cats with and without azotemia and in response to treatment with amlodipine besylate","volume":"28","author":"Jepson","year":"2013","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0230","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0231","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2460\/ajvr.76.9.807","article-title":"Attenuation of the pressor response to exogenous angiotensin by angiotensin receptor blockers and benazepril hydrochloride in clinically normal cats","volume":"76","author":"Jenkins","year":"2015","journal-title":"Am J Vet Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0232","first-page":"855","article-title":"Efficacy of long-term oral telmisartan treatment in cats with hypertension: results of a prospective European clinical trial","volume":"29","author":"Glaus","year":"2018","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0233","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jvim.12062","article-title":"Renin-Angiotensin-Aldosterone System Activity in Hyperthyroid Cats with and without Concurrent Hypertension","volume":"27","author":"Williams","year":"2013","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0234","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2460\/ajvr.1997.58.05.535","article-title":"Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease","volume":"58","author":"Jensen","year":"1997","journal-title":"Am J Vet Res"},{"key":"2026020922225289500_jvim15454-bib-0235","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0236","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1172\/JCI27699","article-title":"Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes","volume":"116","author":"Remuzzi","year":"2006","journal-title":"J Clin Invest"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0237","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/ajkd.2001.20732","article-title":"Relationship between proteinuria and progressive renal disease","volume":"37","author":"Walls","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2026020922225289500_jvim15454-bib-0238","first-page":"44","article-title":"Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials","author":"Geng","year":"2014"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0239","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0240","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1742-1241.2012.02970.x","article-title":"Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis","volume":"66","author":"Cheng","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0241","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0242","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/ndt\/gft281","article-title":"Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial","volume":"28","author":"Esteghamati","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0243","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2460\/ajvr.2003.64.321","article-title":"Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency","volume":"64","author":"Brown","year":"2003","journal-title":"Am J Vet Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0244","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/ki.1993.171","article-title":"Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria","volume":"43","author":"Brown","year":"1993","journal-title":"Kidney Int"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0245","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1939-1676.2000.tb02271.x","article-title":"Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis","volume":"14","author":"Grauer","year":"2000","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0246","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2460\/javma.234.8.1031","article-title":"A randomized controlled clinical trial of the use of benazepril and heparin for the treatment of chronic kidney disease in dogs","volume":"234","author":"Tenhundfeld","year":"2009","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0247","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1292\/jvms.70.455","article-title":"Development of hypertension and effects of benazepril hydrochloride in a canine remnant kidney model of chronic renal failure","volume":"70","author":"Mishina","year":"2008","journal-title":"J Vet Med Sci"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0248","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2460\/javma.2005.226.393","article-title":"Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure","volume":"226","author":"Jacob","year":"2005","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0249","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0021-9975(97)80016-3","article-title":"Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor","volume":"117","author":"Grodecki","year":"1997","journal-title":"J Comp Pathol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0250","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1001\/archinte.1988.00380110024005","article-title":"Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency","volume":"148","author":"Abraham","year":"1988","journal-title":"Arch Intern Med"},{"key":"2026020922225289500_jvim15454-bib-0251","first-page":"716","article-title":"Hemodynamic effects of angiotensin converting enzyme inhibition (Benazepril) in cats with chronic renal insufficiency","volume":"17","author":"Brown","year":"1999","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0252","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0272-6386(12)80696-2","article-title":"Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria","volume":"20","author":"Praga","year":"1992","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0253","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0254","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0255","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.2460\/ajvr.1999.60.12.1516","article-title":"Effect of enalapril on blood pressure, renal function, and the renin-angiotensin-aldosterone system in cats with autosomal dominant polycystic kidney disease","volume":"60","author":"Miller","year":"1999","journal-title":"Am J Vet Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0256","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1111\/jvim.12230","article-title":"Consensus recommendations for standard therapy of glomerular disease in dogs","volume":"27","author":"IRIS Canine GN Study Group Standard Therapy Subgroup","year":"2013","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0257","first-page":"157","article-title":"Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease","volume":"3","author":"Steele","year":"2002","journal-title":"Vet Ther"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0258","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1939-1676.2007.tb03042.x","article-title":"Prognostic factors in cats with chronic kidney disease","volume":"21","author":"King","year":"2007","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0259","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1939-1676.2011.00874.x","article-title":"Clinicopathological variables predicting progression of azotemia in cats with chronic kidney disease","volume":"26","author":"Chakrabarti","year":"2012","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0260","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1939-1676.2006.tb02892.x","article-title":"Survival of cats with naturally occurring chronic renal failure is related to severity of proteinuria","volume":"20","author":"Syme","year":"2006","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0261","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1939-1676.2007.tb02982.x","article-title":"Effect of control of systolic blood pressure on survival in cats with systemic hypertension","volume":"21","author":"Jepson","year":"2007","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0262","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/jvim.13639","article-title":"Comparison of efficacy of long-term oral treatment with telmisartan and benazepril in cats with chronic kidney disease","volume":"29","author":"Sent","year":"2015","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0263","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0895-7061(98)00117-4","article-title":"Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors","volume":"11","author":"Wynckel","year":"1998","journal-title":"Am J Hypertens"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0264","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2460\/javma.2002.221.654","article-title":"Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation","volume":"221","author":"Atkins","year":"2002","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0265","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/jvim.12141","article-title":"Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study","volume":"27","author":"Lefebvre","year":"2013","journal-title":"J Vet Intern Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0266","first-page":"1","article-title":"The influence of enalapril and spironolactone on electrolyte concentrations in Doberman pinschers with dilated cardiomyopathy","volume":"202","author":"Thomason","year":"2014","journal-title":"Vet J"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0267","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jvc.2007.08.002","article-title":"Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg2+, and Na+ concentrations in small dogs with degenerative mitral valve disease","volume":"9","author":"Thomason","year":"2007","journal-title":"J Vet Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0268","first-page":"893","article-title":"mineralocorticoid excess, dietary sodium","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0269","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","article-title":"Remodeling of the rat right and left ventricles in experimental hypertension","volume":"67","author":"Brilla","year":"1990","journal-title":"Circ Res"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0270","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.1016\/0002-9149(93)90239-9","article-title":"Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension","volume":"71","author":"Brilla","year":"1993","journal-title":"Am J Cardiol"},{"issue":"2","key":"2026020922225289500_jvim15454-bib-0271","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/ajh\/4.1.51","article-title":"Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension. Response to captopril","volume":"4","author":"Jalil","year":"1991","journal-title":"Am J Hypertens"}],"updated-by":[{"DOI":"10.1111\/jvim.15615","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000}}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.15454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.15454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.15454","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/33\/2\/363\/66658296\/jvim15454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/33\/2\/363\/66658296\/jvim15454.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:35:04Z","timestamp":1770694504000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/33\/2\/363\/8447946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":271,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.15454","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2019,3,1]]},"assertion":[{"value":"2018-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}